Sébastien Barbarot
0000-0002-6629-9100
CHU de Nantes
246 papers found
Refreshing results…
European guideline ( EuroGuiDerm ) on atopic eczema – part II : non‐systemic treatments and treatment recommendations for special AE patient populations
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Social Media Platforms Listening Study on Atopic Dermatitis: Quantitative and Qualitative Findings. (Preprint)
Non‐acral skin manifestations during the COVID‐19 epidemic: COVIDSKIN study by the French Society of Dermatology
European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics
Executive functions in preschool-aged children with neurofibromatosis type 1: Value for early assessment
Uncommon preputial localization of Langerhans cell histiocytosis
Factors influencing quality of life in children with low‐flow vascular malformations: a qualitative study using focus groups
Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*
Drug survival and postdrug survival of systemic treatments in a national French cohort of children with atopic dermatitis
European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis
COVID‐19 Lockdown induced acral dermatosis in children
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials
TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
The triangular nasal notch sign in patients with Crohn disease treated with tumour necrosis factor inhibitors
Dermatological manifestations of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis ( POIKTMP ): a case series of 28 patients
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
TRE atment of AT opic eczema ( TREAT ) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries
Missing publications? Search for publications with a matching author name.